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lists in hand, new approaches to personalized medicine can be developed by understanding the
assembly of cancer machines using modular domains in proteins and their associated networks.
Using the Src-homology-2 (SH2) domain as an example, new proﬁling approaches can discern global
patterns of tyrosine phosphorylation in cancer cells that can enable molecular cancer medicine.
Identifying and quantifying protein–protein interactions also has the potential to subtype tumors
and guide clinical decision making. These approaches should extend the impact of genomics
through viewing the architecture of cancer systems and improve predictions of patient outcome
and therapeutic response, as well as guide combination therapy approaches that attack cancer
systems.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Personalized cancer medicine
This perspective is written from the viewpoint of a practicing
oncologist interested in applying protein modules and networks
toward new diagnostic and therapeutic approaches to cancer. We
have seen improvements in cancer care over the last decade pro-
duced in large part by a better understanding of the genomic
mechanisms deﬁning cancers [1]. The overarching goal of modern
cancer medicine is to identify tumor subsets that depend on partic-
ular targets for survival and direct therapy against these disease-
speciﬁc drivers of cancer. The ability of practicing clinicians to
match therapy with an individual patient has the potential to dra-
matically improve survival with reduced toxicity. For example, ma-
jor progress has been made against subsets of cancer using
inhibitors of tyrosine kinase signaling molecules as a therapeutic
strategy. Perhaps the best example is the use of imatinib (Gleevec)
for BCR-ABL dependent chronic myelogenous leukemia (CML) [2].
The success of imatinib was heavily inﬂuenced by the knowledge
of the BCR-ABL tyrosine kinase and its critical importance to
leukemia cells. Similar stories include the use of imatinib foral Societies. Published by Elsevier
erapeutics Programs, H. Lee
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3 903 6817.gastrointestinal stromal tumors (GIST), herceptin for HER2 over-
expressing breast cancer, geﬁtinib/erlotinib for epidermal growth
factor receptor (EGFR) mutant driven lung cancers, and crizotinib
for EML4-ALK driven lung cancers [3–6]. Routine molecular testing
for EGFR mutations or EML4-ALK rearrangements, now a standard
practice at our institution and others, have led to personalized
medicine approaches using small molecule tyrosine kinase inhibi-
tors (TKI) to elicit responses and improve outcome for lung cancer
patients [7].
Despite this success using genomic based approaches, a number
of limits exist. Approximately 10% of patients with advanced ade-
nocarcinoma of the lung have activating EGFR mutations and other
tumor types may be lacking classic actionable driver oncogenes.
Tumor responses, both in terms of degree of tumor shrinkage
and time of response, can be heterogeneous. Tumors having a com-
mon oncogene driver (i.e. EGFR mutation) can display differences
in response to TKI, such that degree of tumor shrinkage and time
of response can vary from patient to patient [8,9]. In solid tumors
such as lung and breast cancer, the responses can be short lived
with rapid emergence of resistance and regrowth of the tumor. Re-
sponse heterogeneity has been explained in part by differences in
basal pre-treatment levels of pro-apoptotic proteins, such as BIM,
as well as quantitative differences in pre-existing resistant cells.
Genetic heterogeneity shaped by selection pressures is beingB.V. Open access under CC BY-NC-ND license. 
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next-generation DNA sequencing platforms are starting to describe
this diversity landscape [10,11]. For example, Su found that higher
levels of pre-treatment gatekeeper mutant EGFR alleles (T790M)
that produce EGFR TKI insensitive proteins predicted shorter re-
sponse duration in patients treated with EGFR TKI [12]. Finally,
in addition to increasingly complex biology, questions are begin-
ning to be raised about the true beneﬁt of targeted therapy and
the costs associated with the therapy [13].
Here I will argue that, while major advances have been enabled
by genomic medicine, the next major leap will occur in under-
standing how cancer machine are built from modular domains
and assembled into networks. There is little doubt that genome
based approaches will expand in the future of personalized cancer
medicine. However, an overlapping wave of progress could further
augment the genomic approach by applying lessons learned from
modular domain proteins and their assembly into disease related
networks. Such a view can further identify subsets of cancers not
fully articulated by genomics, can deﬁne new therapeutic targets,
and can start to enable rationale combinations of drugs in an indi-
vidualized fashion.
2. Network medicine
There is increasing recognition that biological networks play an
important role in cancer biology. Rather than single proteins
working in isolation or simple unidirectional pathways, signaling
proteins in cancer behave more as networks, with dense intercon-
nections, multifunctional roles of proteins, reliance on protein
complexes to elicit molecular function, and robustness [14–16].
Cancer is recognized to be a result of changes in cellular genomes
resulting in aberrant signaling proteins causing deregulated cell
growth, survival, and metastasis. These changes rewire entire sig-
naling ‘circuits’ resulting in aberrant growth andmetastasis. Critical
to protein function and signaling is the formation of signaling com-
plexes and networks of signaling proteins that act in concert to
produce a physiological signal [17,18]. State of the art mass spec-
trometry is now able to accurately map protein–protein interaction
(PPI) complexes and signaling networks using phosphoproteomics
[19,20]. This now allows for a more global view of how cancer pro-
teins drive a signaling network to transform cells. The application of
network theory to biology also enables a better understanding of
cancer, improve ability to classify tumors, and suggest therapeutic
approaches against cancer ‘hub’ proteins or suggest rational combi-
nation approaches [14–16,21,22]. In addition, comprehensive PPI
databases (such as www.hprd.org) or phosphorylation databases
(such as www.phosphosite.com) now list protein interactions or
phosphorylation data based on manually annotated reviews of the
literature. Using these databases, groups can construct theoretic
signaling networks that could be important in diseases such as can-
cer. For example, Taylor and colleagues demonstrated that modules
associated with the human interactome could deﬁne populations of
breast cancer patients with distinct prognosis [23]. Cui and col-
leagues used cancer genome data to produce oncogene networks
that appear in solid tumors including breast and lung cancer and
such networks could simplify mutational data when viewed
through a more global approach [24]. Thus, how to make ‘network
medicine’ become a reality [25]?
3. Modules and networks as diagnostics
Early studies using gene expression proﬁling raised awareness
that similarly appearing tumors nonetheless could display marked
differences when viewed through the lens of molecular proﬁling
tools [26,27]. Likewise, tumors proﬁled using mass spectrometry
based approaches demonstrate similar properties. For example,mass spectrometry (MS) coupled with anti-phosphotyrosine (anti-
pTyr) antibodies to proﬁle tyrosine kinase signaling revealed differ-
ent patterns of tyrosine kinase signaling in lung cancer cells and tu-
mors [28]. Overall, this work provided proof of principle that
characterization of global tyrosine phosphorylation patterns can
provide useful information for classifying lung cancers. The impor-
tance of examining global tyrosine phosphorylation is especially
relevant as recent studies have found enrichment of phosphopro-
teins encoded by disease-associated genes and disease seems to
rely on more common evolutionarily conserved networks, includ-
ing cancer that relies on pTyr networks [29,30].
One of the most important consequences of protein tyrosine
phosphorylation is to regulate protein–protein interactions [31].
Many tyrosine-phosphorylated proteins serve as high-afﬁnity
binding sites for proteins containing modular pTyr-speciﬁc binding
domains. These modular domains serve to couple tyrosine phos-
phorylation to the assembly of signaling complexes and the relo-
calization of signaling proteins, and thus play a central role in
downstream signaling. By far the most abundant module in hu-
mans is the Src Homology 2 or SH2 domain [32]. There are 120
SH2 domains encoded by the human genome [33,34], and each
SH2 domain has binding speciﬁcity for a unique spectrum of tyro-
sine phosphorylated sites [35]. Because SH2 domains are what the
cell actually uses to respond to or ‘‘read’’ changes in tyrosine phos-
phorylation ‘‘written’’ by tyrosine kinases, the extent of binding of
different SH2 domains to a cell sample can provide a great deal of
information about the signaling state and its underlying mecha-
nisms. Thus, this approach could be useful in characterizing and
classifying complex tumor types, especially cancers where multi-
ple tyrosine kinases can be driving downstream signaling path-
ways and maintaining tumor growth [1].
Bruce Mayer and his group developed a novel phosphoproteo-
mic method termed SH2 proﬁling, to proﬁle phosphotyrosine
(pTyr) signaling in cancer cells [35–38]. The conceptual basis of
SH2 proﬁling is to take advantage of the cell’s own pTyr binding
motifs and use them as probes for the state of tyrosine phosphor-
ylation of a cell sample. This approach can discern differences in
SH2 proﬁles (and therefore pTyr signaling) in cells transformed
by distinct oncogenic tyrosine kinases [35], and could classify sub-
types of leukemia [36]. Together our two groups recently reported
how SH2 proﬁling can provide information on global tyrosine ki-
nase signaling in lung cancers and how this may be useful for fu-
ture personalized medicine approaches [39]. SH2 domain proﬁles
were generated using a panel of puriﬁed SH2 domains on multiple
lung cancer cell lines that harbor different oncogene mutations
(EGFR, KRAS) as well as display differences in drug sensitivity to
EGFR tyrosine kinase inhibitors. When SH2 domain proﬁles were
examined using unsupervised clustering, we could observe groups
of cells based on SH2 binding patterns with some clusters corre-
lated with EGFR or KRAS mutation status. Amongst cells displaying
identical histology and presence of activating EGFR mutations, we
could observe striking differences in global tyrosine kinase signal-
ing patterns amongst cells in this group, suggesting the added va-
lue of SH2 domains in deﬁning global tyrosine kinase signaling in
cells driven by a common oncogene. For example, cells with hyper-
activated EGFR through mutation could in some instances cluster
amongst cells lacking EGFR mutations. Conversely, we observed
some cell lines that, despite having non-mutated EGFR, had SH2
proﬁles indicative of hyperactive EGFR signaling. We also observed
cells with hyperactivated MET signaling displaying unique patterns
of SH2 binding, suggesting the ability of using modular domain
proﬁling with SH2 domains to read out distinct upstream tyrosine
kinase signaling molecules. Furthermore, a set of SH2 probe bind-
ing correlated with the sensitivity of the cells to EGFR tyrosine ki-
nase inhibitors, suggesting these domains could serve as predictive
biomarkers for TKI therapy. Lastly, SH2 domain binding could be
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could observe similarities in perturbations between two distinct
inhibitors, suggesting overlap of critical targets. Overall this study
illustrates the potential of SH2 domain proﬁles as molecular diag-
nostics to both classify tumors and deﬁne upstream tyrosine ki-
nases vulnerable to attack.
Currently, we are attempting to classify lung cancers taken
directly from patients on the basis of quantitative SH2 proﬁle re-
sults and attempt to correlate with clinical outcomes. We are
interested in identifying patterns of SH2 binding that correlate
with clinically relevant properties of lung cancers, such as EGFR
mutation, pathologic features such as histology and stage, and
with clinical outcomes (survival). Domain proﬁling using SH2
domains could also serve as predictive biomarkers for kinase
inhibitor therapy. By virtue of their ability to read patterns of
tyrosine phosphorylation driven by tyrosine kinases, patterns of
SH2 binding may not simply produce a proxy for genetic onco-
gene addiction but, possibly more importantly, can signal the
presence of multiple tyrosine kinases cooperating in driving tu-
mor growth and survival. Expansion of this approach to improve
feasibility in hospital diagnostic laboratories with streamlined
quantitative analysis could allow for wide scale proﬁling of can-
cers. Finally, dynamic responses of SH2 domains, especially in
the face of kinase inhibitors, may help deﬁne not only acquired
resistance to TKI therapy but also intrinsic resistance. Most re-
ported mechanisms underlying resistance to TKI therapy result
from genetic lesions, such as secondary mutations or gene
ampliﬁcation of other receptor tyrosine kinases that crosstalk
to important signaling pathways [40]. SH2 domains change bind-
ing patterns in response to TKI and in some instances we have
observed increased SH2 binding despite inhibition of tyrosine ki-
nase signaling with TKI. It remains to be determined if SH2 do-
mains facilitate formation of new complexes in the face of TKI
therapy and if this is one way for tumors to survive TKI therapy.
While activation of other kinases (including those with SH2 do-
mains) is frequent in drug resistance, little attention has been
paid to the ability of non-catalytic adaptor proteins with modu-
lar domains such as SH2 that can form new complexes following
TKI therapy. CRK-L, for example, has recently been implicated as
a non-kinase SH2 containing adaptor program that can mediate
TKI resistance in lung cancer cells addicted to EGFR [41].4. Translating interactomes into molecular proﬁles
Encouraged by the results using SH2 domains that identify dis-
tinct patterns of pTyr within a common oncogene genotype (EGFR),
our lab and the Superti-Furga lab are undertaking a system wide
and global analysis of the protein–protein interactomes driven by
hyperactivated EGFR resulting from somatic mutation in lung can-
cer [42–44]. Our approach has been to use tandem afﬁnity puriﬁ-
cation – mass spectrometry (TAP-MS) in cell models that harbor
mutant EGFR proteins and are highly sensitive to EGFR TKI. Tagged
versions of EGFR are initially used to identify interactions and sec-
ond round of TAP-MS is performed to more fully construct the net-
work [45]. This interaction network will allow functional
interrogation of targets important in driving mutant EGFR growth
and survival signals. The interactions themselves could deﬁne an
addicted EGFR reference map and, similar to observed with SH2
domains, differences in the interactome could further deﬁne differ-
ent subtypes of tumor cells within a common genotype. This could
be relevant to clinical observations of different degrees of response
to EGFR TKI despite same gentoypes and emergence of resistant
cells [8,40]. Thus, the critical question becomes, how can one
‘translate’ these highly sophisticated interactome data, whethergenerated by mass spectrometry or other approaches, and actually
detect and quantify interactomes in human cancer samples?
Translation of these interactome approaches to tumor samples
is hampered by a number of hurdles. First, almost all studies have
been carried out in engineered mammalian cells that express a
tagged version of the protein of interest; this limits the ability to
use these modern TAP-MS approaches in samples from patients.
Second, most samples from patients in clinical practice are forma-
lin ﬁxed and parafﬁn embedded. This precludes the ability to use
fresh frozen tissue for immunoprecipitation and western blotting
(IP-WB) to identify protein complexes. IP-WB also requires a large
amount of starting material that can be difﬁcult to obtain with nee-
dle biopsies. One solution to mapping networks identiﬁed using
MS-based proteomics is proximity ligation assays (PLA) [46–51].
Brieﬂy, two proteins in complex are each identiﬁed with primary
antibodies speciﬁc for the protein and linked to a conjugated oligo-
nucleotide. A connector oligonucleotide links both proximity
probes allowing ligation and formation of a template for PCR
ampliﬁcation. The resulting rolling circular ampliﬁcation (RCA)
serves as a target for hybridized ﬂuorescently labeled detection oli-
gonucleotides allowing distinct and bright spots to be identiﬁed
and quantiﬁed in a ﬂuorescent microscope. See http://www.olink.-
com/movie.php for a graphic movie of this technology. This
technology has been used to identify in cells in situ Myc–Max
interactions, tyrosine phosphorylation of receptor tyrosine kinases,
and interactions of proteins in human tissue sections.
As little has been done to establish biomarker systems to mea-
sure protein–protein based biomarkers in cancer, our group is cur-
rently developing PLA that can quantitatively measure deﬁned
EGFR protein–protein interactions in lung cancer specimens and re-
late expression of these interactions to clinical outcome variables.
The approach to develop biomarkers based on in situ protein–
protein interactions goes one step beyond measurement of protein
expression as it determines the binding to two proteins together in
tumor tissues. Two proteins may be equally expressed, but because
of other nuances in the cancer cell, do not form a signaling complex
that drives a signaling cascade. In another tumor cell, these pro-
teins form a complex and drive a signaling cascade. Gene-based
approaches that measure mRNA expression or immunohistochem-
istry approaches that measure protein expression would be unable
to discriminate these two cases. Conceptually, we can build on our
interactome maps, either directly generated through mass spec-
trometry based experiments or through databases data, to con-
struct in situ protein–protein interaction networks in patient
based materials. This may lead to further subtyping a cancer de-
spite common genotype and mark interactions as targets for future
chemistry.5. Challenges
It is becoming more apparent that cancers, especially solid tu-
mors such as lung cancer, are the result of multi-gene hits resulting
from environmental insults coupled with genetic predispositions
to development of cancer. This includes gain or loss of multiple
chromosomal elements within single tumors as well as multiple
mutations in cancer causing genes such as kinases [52–54]. It is
clear that genotypes will be a common diagnostic tool for practicing
physicians yet important nuances of cancers could still be realized
through views of how modular domains organize in tumor cells.
One of the challenges is to understand how all these genetic
changes ultimately converge on growth, survival, and metastasis
signaling programs to allow the development of cancer. Here
network analysis approaches can help integrate various genomic
data to produce cohesive views of deregulated pathways affecting
In Situ Protein InteractomesModular Domain Binding Patterns
Molecular Profiles for Personalized Medicine
Genotypes
Fig. 1. A role for modular domain binding patterns and interactome networks in molecular medicine. Tumor tissues will receive genotype analysis to examine from driver
mutations in oncogenes and/or examine for loss of tumor suppressor genes that represent different subtypes of tumors based on genotypes. Modular domain binding
patterns, for example SH2 domains that recognize phosphotyrosine, can produce additional views of tumors. In the case demonstrated here, SH2 domain proﬁling can identify
a strong pattern of SH2 binding in tumor cells (red). Similarly, pre-deﬁned protein–protein interactions measured using proximity ligation assays can identify tumor
interactomes that could further classify tumors. On the right, red foci indicate interactions between EGFR and Grb2 proteins measured using proximity ligation assays, nuclei
are identiﬁed with DAPI (blue) and tumor cells identiﬁed using cytokeratin (green). Development of these approaches into validated biomarker systems could classify tumors
and provide information relevant for clinical care, including prognostic measures as well as predictive biomarkers for drug therapy. SH2 domain ﬁgure is shown as published
in Ref. [39].
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changes to deﬁne novel therapeutic opportunities for patients with
cancer. One of the limits of current cancer medicine is the lack of
rationale combinations of molecularly targeted agents. One can
view progress in other diseases, especially infectious diseases, to
get clues about how to make progress in cancer. For example, man-
agement of HIV progressed from single agent antiretroviral therapy
with AZT to multi-agent antiviral therapy (HAART) [56]. Therefore,
combination approaches against a system can be highly effective in
treating complex diseases. Translation of the underlying science of
how cancer proteomes are assembled using their modular domains
could be one way forward towards rationale combinations of path-
way inhibitors designed and personalized for each individual’s can-
cer (Fig. 1). In the near future it is likely to have the entire cancer
parts list at the ﬁngers for oncologists, yet assembly of these enor-
mous datasets into a cohesive and integrated cancer system that
predicts vulnerability will limit efﬁcacy of such datasets. Down-
sides of such an approach is the logistical hurdles of combination
therapy related to regulatory development of compounds, eco-
nomic cost, and potential for serious toxicity when manipulating
multiple signaling proteins in normal tissues. Better predictions
of the activity of therapeutics is critical, as testing multiple com-
pounds and combinations in patients with cancer is prohibitive
for a number of reasons, such as limited ﬁnancial resources, difﬁ-
culties with combinations of unapproved agents, and low enroll-
ment on clinical trials [57,58]. As we have discussed here, the
biology of modular domains on a system wide level could tease
out differences that could be important from a prognostic or ther-
apeutic vantage point [59]. Towards this end, systems medicine
teams need to be created and supported to handle the multi-
dimensional data and provide enough statistical support for bio-
marker development.
Lastly, will we see new attempts to disrupt signaling using
drugs acting as disruptors of protein–protein interactions orremodelers of signaling using principles of synthetic biology?
[60] One of the larger drug targets has been kinases and this has
led to many targets being developed with large amounts of aca-
demic and industry overlap [61]. However, most solid tumors ad-
dicted to oncogenes demonstrate resistance mechanisms that can
be hard to overcome with subsequent therapeutics. This raises
the possibility of using protein–protein interaction disrupters to
produce additional pressure on tumor cells to escape drugs target-
ing their addiction mechanisms [62]. Recent reviews highlight
emerging approaches to develop compounds disrupting protein–
protein interactions and early results of compounds in human clin-
ical trials, such as navitoclax and obatoclax that disrupt Bcl2 family
complexes, have been reported [63–65]. One could also hope to see
new therapeutics built upon synthetic biology that promote rewir-
ing modular domains and networks to drive tumor cells back to-
wards a normal state.
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